Axogen, Inc. (AXGN)
NASDAQ: AXGN · Real-Time Price · USD
23.99
+0.61 (2.61%)
At close: Nov 6, 2025, 4:00 PM EST
23.52
-0.47 (-1.96%)
After-hours: Nov 6, 2025, 6:21 PM EST
Axogen Revenue
Axogen had revenue of $60.08M in the quarter ending September 30, 2025, with 23.51% growth. This brings the company's revenue in the last twelve months to $214.71M, up 18.72% year-over-year. In the year 2024, Axogen had annual revenue of $187.34M with 17.81% growth.
Revenue (ttm)
$214.71M
Revenue Growth
+18.72%
P/S Ratio
5.14
Revenue / Employee
$475,020
Employees
452
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 187.34M | 28.33M | 17.81% |
| Dec 31, 2023 | 159.01M | 20.43M | 14.74% |
| Dec 31, 2022 | 138.58M | 11.23M | 8.81% |
| Dec 31, 2021 | 127.36M | 15.06M | 13.41% |
| Dec 31, 2020 | 112.30M | 5.59M | 5.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AXGN News
- 1 day ago - Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 8 days ago - Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Axogen, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN - Business Wire
- 5 weeks ago - AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 2 months ago - Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft - GlobeNewsWire
- 3 months ago - Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined - Seeking Alpha
- 3 months ago - Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript - Seeking Alpha